LGALS3 and systemic sclerosis: used a galectin level threshold above 10.25ng/mL, which is independently associated with all-cause mortality in systemic sclerosis (122), to divide their cohort into two groups; those with higher levels had 64% positivity for IgG4 anti-galectin-3 antibodies, whilst those with lower levels had 23% positivity (121).